915194-00-2

Usage

Uses

Used in Pharmaceutical Research:
L-Glutamic acid, 5-cyclohexyl 1-(phenylmethyl) ester is used as a potential treatment for various conditions due to its neuroprotective and antioxidant properties. These properties make it a promising candidate for the development of medicines targeting neurological disorders or oxidative stress-related conditions.
Used in Neurological Disorders:
L-Glutamic acid, 5-cyclohexyl 1-(phenylmethyl) ester is used as a potential therapeutic agent for neurological disorders, leveraging its neuroprotective properties to potentially alleviate symptoms and improve patient outcomes.
Used in Oxidative Stress-Related Conditions:
L-Glutamic acid, 5-cyclohexyl 1-(phenylmethyl) ester is used as a potential treatment for oxidative stress-related conditions, utilizing its antioxidant properties to combat the harmful effects of oxidative stress on the body.
Further studies are needed to determine the safety and efficacy of L-Glutamic acid, 5-cyclohexyl 1-(phenylmethyl) ester in clinical settings.

Upstream product

• 100-39-0 benzyl bromide 
• 73821-97-3 N-α-tert-butyloxycarbonyl-glutamic acid, γ-cyclohexyl ester 
• 73821-96-2 (2S)-tert-butoxycarbonylamino-pentanedioic acid 1-benzyl ester 5-cyclohexyl ester 

Relevant academic research and scientific papers

Potent and fully noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein

Nα-Boc-l-Asp(OBn)-l-Lys(Z)-OtBu (reversin 121, 1), an inhibitor of the P-gp ABC transporter, was used to conceive compounds inhibiting the drug efflux occurring through the Hoechst 33342 and daunorubicin transport sites of P-gp, respectively H and R sites. Replacement of the aspartyl residue by trans-4-hydroxy-l-proline (4(R)Hyp) gave compounds 11 and 15 characterized by half-maximal inhibitory concentrations (IC50) of 0.6 and 0.2 μM, which are 2-and 7-fold lower than that of the parent molecule. The difference in IC50 between 11 and 15 rests on the carbonyl group of the peptidyl bond, reduced in 15. Those compounds are rather specific of P-gp, having no or limited activity on MRP1 and BCRP. 15 displayed no marked cytotoxicity up to 10-fold its IC50. Importantly, 15 equally inhibited the Hoechst 33342 and daunorubicin effluxes through a typical noncompetitive inhibition mechanism, suggesting its binding to a site different from the H and R drug-transport sites.

Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins

Several aminomethylene analogs and a ketomethylene analog of reversins were synthesized in order to evaluate their ability to inhibit P-glycoprotein-mediated drug efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein. These analogs retained

Solution-phase automated synthesis of tripeptide derivatives

An improved general method for automated synthesis of tripeptides was developed, in which methanesulfonic acid (MSA) was used in place of trifluoroacetic acid (TFA), thus making it possible to avoid, 1) corrosion of the apparatus by strong acid vapor, 2) formation of emulsions, and 3) use of the restricted solvent, dichloromethane. As an application of the automated synthesis apparatus, 216 fragment tripeptide derivatives were synthesized systematically using the MSA method, in excellent yield and with increased efficiency.

Application of a unique automated synthesis system for solution-phase peptide synthesis

An automated synthesis system, which is suitable for repetitive syntheses using similar reaction procedures, was used to synthesize systematically a library of all possible dipeptides (25) and tripeptides (125) from 5 protected amino acids. The apparatus has also been applied to the automated synthesis of 10 fragment tripeptide derivatives that are constituents of the hormone PACAP-27. The measured molecular optical rotation values of the library of 125 tripeptides were found to correlate well with calculated values obtained by summation of the molecular optical rotation values for the constituent amino acids.